The Effectiveness Based on Optimal Dose and Administration Route, and Safety Profiles of Stem Cells and Derived Products in the Treatment of Patients With Amyotrophic Lateral Sclerosis: A Systematic Review and Meta‐Analysis
Stem Cells International · 2026-01 · 2026 (1)
DOI: 10.1155/sci/4122493 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cells International, online erschienen am 05.08.2026. Verfasst von Mahdieh Pourasghari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, tbzmed.ac.ir. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
This systematic review and meta‐analysis aimed to evaluate the effectiveness of stem cell therapies for patients with amyotrophic lateral sclerosis (ALS) based on optimal dosing and administration routes, as well as the safety profiles of stem cells and their derived products.
Methods
The review followed PRISMA guidelines and involved a comprehensive literature search up to October 2025, receiving ethical approval from Tabriz University of Medical Sciences and registration in PROSPERO. It utilized international databases, including PubMed/MEDLINE, Embase, Cochrane Library, Scopus, Web of Science, ProQuest, ClinicalTrials.gov, and Science Direct. The included studies comprised randomized controlled trials (RCTs), quasi‐experimental studies, and other interventional designs involving ALS patients treated with stem cell therapies. In total, 31 studies were analyzed, featuring 7 controlled trials with 370 participants and 24 non‐controlled pre–post studies with 460 participants. Heterogeneity was evaluated using I 2 statistics, and subgroup analyses were conducted based on treatment duration and dosing.
Results
A pooled analysis (treatment group: n = 93; control group: n = 90) demonstrated a significant attenuation in the progression of disease severity, as measured by the ALS Functional Rating Scale (ALSFRS), in stem cell groups versus controls (weighted mean difference [WMD]: 8.89 95% CI: 4.12–13.67; p = 0.0003), which was beneficial for both the ≥10 × 10 6 and
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran, tbzmed.ac.ir.
- Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran, tbzmed.ac.ir.
ORCID-Profile: Mahdieh Pourasghari, Soraya Babaie, Raha Markazi-Movaghar, Saba Salehpour, Bina Eftekharsadat, Azizeh Farshbaf-Khalili
Zitieren
APA
Pourasghari, M., Babaie, S., Markazi-Movaghar, R., Salehpour, S., Eftekharsadat, B., & Farshbaf-Khalili, A. (2026). The Effectiveness Based on Optimal Dose and Administration Route, and Safety Profiles of Stem Cells and Derived Products in the Treatment of Patients With Amyotrophic Lateral Sclerosis: A Systematic Review and Meta‐Analysis. Stem Cells International, 2026(1). https://doi.org/10.1155/sci/4122493
Vancouver
Pourasghari M, Babaie S, Markazi-Movaghar R, Salehpour S, Eftekharsadat B, Farshbaf-Khalili A. The Effectiveness Based on Optimal Dose and Administration Route, and Safety Profiles of Stem Cells and Derived Products in the Treatment of Patients With Amyotrophic Lateral Sclerosis: A Systematic Review and Meta‐Analysis. Stem Cells International. 2026;2026(1). doi:10.1155/sci/4122493
BibTeX
@article{Pourasghari2026,
author = {Pourasghari, Mahdieh and Babaie, Soraya and Markazi-Movaghar, Raha and Salehpour, Saba and Eftekharsadat, Bina and Farshbaf-Khalili, Azizeh},
title = {The Effectiveness Based on Optimal Dose and Administration Route, and Safety Profiles of Stem Cells and Derived Products in the Treatment of Patients With Amyotrophic Lateral Sclerosis: A Systematic Review and Meta‐Analysis},
journal = {Stem Cells International},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/sci/4122493}
}
EUVIMED